MGI Saforis NDA To Be Based On Single Phase III Trial; Filing Planned For Q3
Executive Summary
MGI Pharma expects to file an NDA for Saforis (l-glutamine oral suspension) for the treatment of oral mucositis based on the results of one Phase III trial and supportive earlier-phase trials
You may also be interested in...
MGI Dacogen Launch Plans Stress Efficacy Profile, Treatment Duration
MGI will highlight the efficacy profile of its myelodysplastic syndromes therapy Dacogen when detailing decitabine to oncologists
Aloxi Sees Share Gains, Volume Drop In First Month Under Medicare ASP
MGI Pharma's anti-emetic Aloxi (palonosetron) gained market share in the first month of average sales price-based reimbursement despite a drop in prescription volume for the class
Amgen Kepivance To Launch In January; Additional Mucositis Trials Underway
Amgen will launch the oral mucositis treatment Kepivance (palifermin) in late January following FDA approval Dec. 15